Suzhou-based Biotech Xinjing Zhiyuan Secures Over RMB 200 Million in Series B Funding to Advance TCR-T Therapies for Solid Tumors
Neowise
Solid Tumor TCR-T Cell Therapy Drug Developer
On January 26, Neowise Biotechnology announced the completionOver 200 Million Yuan in Series B FinancingThis round of financing was jointly led by Apricot Capital and a well-known industrial fund, with follow-up investments from Delian Capital, Yuanhe Holdings, and Suzhou Angel Mother Fund. Existing shareholders Tonggao Capital and GEM continued to strongly support the company. Heryue Capital served as the exclusive financial advisor for this round of financing.
Source:Neowise Biotechnology Official WeChat
Neowise Biotechnology was founded in 2020, with its headquarters located in Suzhou.Focus on the Development of TCR-T Immunotherapy Drugs for Solid TumorsThe company has independently developed a high-throughput, high-sensitivity target antigen-natural TCR discovery platform. By combining computational and experimental validation through iterative feedback, it efficiently screens for natural high-affinity TCR sequences that specifically recognize tumor antigens, establishing a globally leading, experimentally validated tumor target antigen-natural TCR pairing database.（CAST®）。
Currently, Neowise Biotechnology has multiple pipelines that have advanced to the clinical trial stage. In clinical trials targeting various solid tumors, positive efficacy and good safety have been observed.
Among them,NW-101C It is independently developed by Neowise Biotechnology,Targeting PRAMEThe TCR-T cell therapy candidate isThe first product in China to enter the clinical stage for this target, has achieved positive efficacy in a variety of advanced solid tumors. Currently, this investigational drug is undergoing Phase I registrational clinical trials, with indications including ovarian cancer, malignant melanoma, esophageal squamous cell carcinoma, squamous cell carcinoma of the lung, soft tissue sarcoma, and triple-negative breast cancer, among others.
NW-301V is a product independently developed by Neowise Biotechnology.Targeting KRAS G12V MutationThe TCR-T cell therapy candidate, whose preliminary clinical study results were presented as a preferred oral report at the 2025 ESMO Annual Meeting. (proffered paper presentation) in the form of publication, this is the world's first systematic disclosure of clinical data for TCR-T drugs targeting this site.
In the 14 evaluable patients with advanced colorectal cancer, pancreatic cancer, etc., enrolled as of July 2025, NW-301V demonstrated good safety and efficacy. In terms of safety, no dose-limiting toxicity or serious adverse reactions were observed. Regarding efficacy, the objective response rate was observed in 10 subjects treated with medium and high dose groups.（ORR）Up to 50%, Disease Control Rate（DCR）Up to 100%.
According to the press release, the funds from this round will be mainly used for clinical research on Neowise Biotechnology's core pipeline and the advancement of multiple pre-clinical pipelines, accelerating the process of the company’s innovative drugs moving towards clinical trials, commercialization, and internationalization.
